

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

AquaVac PD3 emulsion for injection for Atlantic salmon

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each dose of 0.1 ml contains:

#### **Active substances:**

Salmon pancreas disease virus (SPDV), strain F93-125, inactivated  $\geq 75\%$  RPP<sup>1</sup>

Infectious pancreatic necrosis virus (IPNV), inactivated  $\geq 1.5$  ELISA units<sup>2</sup>

*Aeromonas salmonicida*, subsp. *salmonicida*, inactivated  $\geq 80\%$  RPS<sub>60</sub><sup>3</sup>

<sup>1</sup> RPP: relative percentage protection in a laboratory test in Atlantic salmon

<sup>2</sup> Antigenic mass measured in the final product

<sup>3</sup> RPS<sub>60</sub>: relative percentage survival at 60% control mortality in a laboratory test in Atlantic salmon

#### **Adjuvant:**

Light liquid paraffin, 43 mg

#### **Excipients:**

<b>Qualitative composition of excipients and other constituents</b>
Polysorbate 80
Sorbitan monooleate
Phosphate buffered saline

White to nearly white emulsion.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Atlantic salmon.

#### **3.2 Indications for use for each target species**

For active immunisation of Atlantic salmon to reduce clinical signs (heart lesions and pancreas lesions), viremia, viral shedding and mortality from infection with SPDV (Pancreas disease) and to reduce mortality from infections with IPNV (Infectious pancreatic necrosis) and *Aeromonas salmonicida* subsp. *salmonicida* (furunculosis).

Onset of immunity: 500 degree days after vaccination for SPDV and *Aeromonas salmonicida* and 540 degree days after vaccination for IPNV.

Duration of immunity: demonstrated at 15 months post vaccination for SPDV and at 16 months post vaccination for *Aeromonas salmonicida*. Protection against mortality due to IPNV infection has been demonstrated at 4 months post vaccination in the field.

### **3.3 Contraindications**

None.

### **3.4 Special warnings**

Vaccinate healthy animals only.

### **3.5 Special precautions for use**

Special precautions for safe use in the target species:

Do not use in fish during smoltification.

Incorrect vaccination, stress and poor hygiene may lead to increased side effects.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Personal protective equipment consisting of e.g. needle protector should be used when handling the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Atlantic salmon:

Very common (>1 animal / 10 animals treated):	Melanin accumulation in fish <sup>1</sup> , visible vaccine in fish <sup>1</sup> , adhesion in fish <sup>2</sup> .
Common (1 to 10 animals / 100 animals treated):	Adhesion in fish <sup>3</sup> .
Uncommon (1 to 10 animals / 1,000 animals treated):	Adhesion in fish <sup>4</sup> .

<sup>1</sup> Observed in the abdominal cavity.

<sup>2</sup> Speilberg scores 1-3 during the fresh water phase up to sea transfer, Speilberg scores 1-2 during the sea water phase.

<sup>3</sup> Speilberg score 3 during the sea water phase.

<sup>4</sup> Speilberg score 4 during the fresh water phase up to sea transfer.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

#### Fertility:

Do not use in broodstock. The possible effects of vaccination on spawning have not been investigated.

### 3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

### 3.9 Administration routes and dosage

Intraperitoneal use.

Dose: a single dose of 0.1 ml.

Administration: intraperitoneally along the central line, approximately 1 pelvic fin length in front of the pelvic fin base in Atlantic salmon. Shake the bottle well before use.

Vaccination is recommended for fish above 30 grams.

Food should be withheld for sufficient time (at least 48 hours) to ensure emptying of the gut prior to vaccination. The fish should be anaesthetised before vaccination. The length and the diameter of the applied needle should be adapted to the actual fish size. Ensure that the recommended dose is deposited into the abdominal cavity before the needle is withdrawn.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

After administration of a double dose more vaccine residues can be observed, but no increase in local reactions is observed compared to single dose administration.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Zero degree days.

## **4. IMMUNOLOGICAL INFORMATION**

### **4.1 ATCvet code: QI10AL.**

The product stimulates active immunity against pancreas disease, infectious pancreatic necrosis, and furunculosis.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 19 months.  
Shelf life after first opening the immediate packaging: use within 1 working day.

### **5.3 Special precautions for storage**

Store in a refrigerator (2 °C – 8 °C).  
Do not freeze.

### **5.4 Nature and composition of immediate packaging**

Bottles of polyethylene terephthalate (PET) closed with a rubber stopper and aluminium cap.

Pack size:  
500 ml (5,000 doses).

**5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

MSD Animal Health UK Limited

**7. MARKETING AUTHORISATION NUMBERS**

Vm 01708/3038  
Vm 01708/5108

**8. DATE OF FIRST AUTHORISATION**

26 March 2015

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

March 2025

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT**

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

*Gavin Hall*

Approved: 02 July 2025